Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2009

View Archived Issues

Trastuzumab treatment for breast cancer associated with cardiotoxicity

Clopidogrel triple therapy effective in AMI in diabetics; novel approach to clopidogrel described

Takeda claims novel tyrosine kinase inhibitors

Novel annelated pyridazines claimed by Amgen for cancer treatment

Jenrin Discovery claims novel cannabinoid receptor antagonists

Novel compounds for the treatment of hepatitis C claimed by Abbott

Novel beta2-adrenoceptor agonists described by Sepracor for the treatment of bronchoconstriction

Improvement of Raynaud's phenomenon seen with topical nitroglycerin formulation MQX-503

GENZ-112638 shows safety and efficacy in phase II trial for Gaucher's disease

Daiichi completes patient enrollment in phase III clinical trial of influenza drug CS-8958

Diamyd to combine U.S. and European phase III trials of diabetes vaccine Diamyd

Flecainide shows promise in catecholaminergic polymorphic ventricular tachycardia therapy

NexBio forms clinical advisory board for influenza drug Fludase

FDA accepts for review Vion's NDA for Onrigin in AML

DSMB recommends continuation of phase IIb study of Rockwell's SFP in ESRD

Can-Fite commences phase I/II CF-102 trial in liver cancer

Cangene obtains rights to commercialize certain biotech drugs from Apotex

Clavis initiates phase II intravenous CP-4126 trial in advanced pancreatic cancer

GlaxoSmithKline and Pfizer enter agreement to create a new HIV company

GlobeImmune initiates phase I Tarmogen trial in CEA-overexpressing cancers

Stanford study of malaria vaccine requires more participants

Viral Genetics pursues promising new Lyme disease therapy with new grant

Copaxone approved by Health Canada for isolated syndrome suggestive of MS

Virionyx changes name to Innate Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...